Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.
The capability of pravastatin and lovastatin, HMG-CoA reductase inhibitors likely to be taken chronically for hypercholesterolemia, to cross the blood-brain barrier was investigated in normal male volunteers. Lovastatin, which is lipophilic, was detected in cerebrospinal fluid (CSF) at concentrations that may have a pharmacologic effect. Pravastatin, which is hydrophilic, was not detected in CSF. It is concluded that pravastatin may have less potential for causing CNS-related side effects than lovastatin.
Botti
R E
RE
Bristol-Myers Squibb Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000.
Triscari
J
J
Pan
H Y
HY
Zayat
J
J
D000328:Adult; D000924:Anticholesteremic Agents / Q000134:cerebrospinal fluid* / Q000493:pharmacokinetics; D001812:Blood-Brain Barrier; D006538:Heptanoic Acids / Q000134:cerebrospinal fluid* / Q000493:pharmacokinetics; D006801:Humans; D008148:Lovastatin / Q000134:cerebrospinal fluid* / Q000493:pharmacokinetics; D008297:Male; D009281:Naphthalenes / Q000134:cerebrospinal fluid* / Q000493:pharmacokinetics; D017035:Pravastatin; D012016:Reference Values
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D009281:Naphthalenes; D008148:Lovastatin; D017035:Pravastatin